Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
News for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) centers on its role as a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated skin diseases. Company announcements frequently highlight developments in its ZORYVE (roflumilast) topical franchise for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, along with updates on its broader immuno-dermatology pipeline.
Investors and clinicians following ARQT news can expect detailed coverage of regulatory milestones, such as U.S. Food and Drug Administration (FDA) approvals and supplemental new drug application (sNDA) acceptances for new age groups and indications. Releases describe label expansions for ZORYVE cream and foam, including approvals for pediatric atopic dermatitis and seborrheic dermatitis, and FDA review timelines for potential new pediatric plaque psoriasis indications.
Arcutis also reports on clinical trial progress and data presentations. Recent news includes completion of enrollment in pediatric studies like INTEGUMENT-INFANT, publication of long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, and new Phase 3 analyses showing improvements in itch, sleep disruption, and long-term disease control with ZORYVE cream 0.15% and 0.05% in atopic dermatitis.
Financial and corporate updates form another key news category. The company issues quarterly earnings releases detailing net product revenue for ZORYVE, outlines strategies for sustainable growth, and provides guidance on future net product sales. Additional items include inducement equity grants, participation in investor conferences, and board-level changes disclosed via press releases and Form 8-K filings.
News flow also covers pipeline and strategic priorities, such as Phase 2 proof-of-concept trials of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and early clinical development plans for ARQ-234, a CD200 receptor checkpoint agonist being developed as a potential biologic for atopic dermatitis. Together, these updates give readers insight into Arcutis’ commercial performance, regulatory trajectory, and ongoing research in immuno-dermatology.
Arcutis Biotherapeutics (NASDAQ: ARQT) announced the publication of positive Phase 3 trial results for ZORYVE® (roflumilast) foam 0.3% in JAMA Dermatology. The ARRECTOR trial evaluated the treatment in 432 patients with scalp and body psoriasis across 49 sites in the US and Canada.
Key results at Week 8 showed: 66.4% of patients achieved Scalp-IGA success vs 27.8% for vehicle, 45.5% achieved Body-IGA success vs 20.1% for vehicle, and 65.3% experienced significant scalp itch reduction vs 30.3% for vehicle. Notably, improvement in itch was observed within 24 hours of first application.
The treatment was well-tolerated with low incidence of adverse events. An sNDA is under FDA review with a PDUFA date of May 22, 2025.
Arcutis Biotherapeutics (NASDAQ: ARQT) has granted a total of 26,500 restricted stock units (RSUs) to three newly hired employees. The awards were approved by the company's Compensation Committee and granted under the Arcutis Biotherapeutics 2022 Inducement Plan on May 1, 2025. The RSUs will vest over a four-year period, with 25% vesting on each annual anniversary of the vesting commencement date, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new employees joining the company.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its first quarter 2025 financial results announcement for May 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the 'Events' section of Arcutis' website, with an archived replay available afterward on the company's investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a planned CFO transition, with David Topper retiring and Latha Vairavan, current VP and controller, taking over the position. The transition will be effective after the Q1 10-Q filing, with Topper providing support through May 15, 2025.
During his tenure since April 2024, Topper made significant contributions including renegotiating the company's debt facility with SLR Investment Corp, revamping investor relations strategy, and leading the transition to large accelerated filer status. Vairavan, who joined Arcutis in 2020, brings over 20 years of biotech industry finance experience, including 12 years at Amgen.
The company highlighted continued market momentum for their product ZORYVE® (roflumilast) in inflammatory skin conditions. Vairavan will focus on further commercialization efforts and maintaining the company's financial position.
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 35,000 restricted stock units to five newly hired employees. The grants were approved by the company's Compensation Committee and issued under the Arcutis Biotherapeutics 2022 Inducement Plan on April 1, 2025.
The restricted stock units feature a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. Continuous employment is required for vesting. This grant was made as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT) and Padagis have agreed to stay their ongoing patent litigation regarding ZORYVE® cream 0.3%. The joint stipulation, filed in the U.S. District Court for the District of Delaware on April 2, 2025, will vacate all calendared dates and trial.
Under the agreement, Padagis must report any FDA correspondence regarding their ANDA for a potential generic alternative to ZORYVE. The parties agreed to extend the 30-month Hatch-Waxman stay of regulatory approval by one day for every day the litigation is stayed from March 24, 2025.
ZORYVE, protected by patents until at least 2037, is indicated for topical treatment of plaque psoriasis in patients 6 years and older. The company maintains confidence in their patent portfolio and will continue defending their intellectual property rights if the stay is lifted.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company will engage in a fireside chat on Tuesday, April 8, 2025, at 11:00 am EDT. The conference is scheduled to run from April 7-10, 2025. Interested parties can access the webcast through the 'Events' section of Arcutis' website, with the recording remaining available for 180 days after the conference.
Arcutis Biotherapeutics (ARQT) presented new data from Phase 3 trials at the 2025 American Academy of Dermatology Meeting, showcasing results for ZORYVE® treatments in psoriasis and atopic dermatitis (AD).
The INTEGUMENT 1-2 trials (n=1,337) demonstrated positive efficacy of ZORYVE cream 0.15% in AD patients with prior inadequate response to conventional treatments. Over 91% of participants reported no or mild application site sensation, and ≥97% showed no or minimal irritation.
The ARRECTOR trial revealed significant improvements in patient-reported outcomes for ZORYVE foam 0.3% in scalp and body psoriasis, showing enhanced quality of life across 23-component Scalpdex assessment during the eight-week study period.
- AD affects ~26 million adults and children in the US
- Psoriasis impacts ~9 million US adults and children, with over half experiencing scalp involvement
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 27,000 restricted stock units to three newly hired employees. The grants were approved by the company's Compensation Committee and issued under the Arcutis Biotherapeutics 2022 Inducement Plan on March 3, 2025.
The restricted stock units feature a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. Continued employment with Arcutis is required for vesting. The grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).